secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-07-22T20:05:19+00:00
Accession:  0001193125-26-312391
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest partners with Senlang to develop TPST-4003 in vivo CAR-T; IIT in China expected Q4 2026
--------------------------------------------------------------------------------

- Collaboration with Hebei Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T candidate.
- First-in-human IIT in ~10 patients with myasthenia gravis or multiple sclerosis; first dosing Q4 2026.
- Development fee range $1.5M-$2.0M per product; Senlang gets exclusive option for China rights.
- Initial safety and PD data expected first half 2027.
- Tempest retains all IP; Senlang will conduct trial in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/0001193125-26-312391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526312391/d107304d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-312391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer